drugset / Trial / NCT06252220
First in Human Study in Subjects With Obesity, But Otherwise Healthy
RandomizedSequentialTriple-blindTreatment
Summary
This is a First in Human study to evaluate the safety and tolerability of DA-1726 following single and multiple doses in participants with obesity, but otherwise healthy subjects.
Timeline
- Start
- 2024-03-25
- Primary completion
- 2026-11-09
- Completion
- 2026-11-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | DA-1726 | Unknown | — | Subcutaneous |